Go Pro

Dyne Therapeutics (DYN) 10K Form and Latest SEC Filings 2026

Dyne Therapeutics logo
$15.20 -0.62 (-3.92%)
Closing price 04:00 PM Eastern
Extended Trading
$15.32 +0.13 (+0.82%)
As of 05:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Dyne Therapeutics SEC Filings & Recent Activity

Dyne Therapeutics (NASDAQ:DYN) has submitted 592+ documents to the U.S. Securities and Exchange Commission (SEC) since 2020. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Dyne Therapeutics's financial statements. The most recent filing was a Form 8-K submitted on September 29, 2026.

Form 4
Dyne Therapeutics, Inc. Reports Ownership Change on Sep. 8, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Dyne Therapeutics Files Current Report on Sep. 29, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Dyne Therapeutics Files Quarterly Report on May. 11, 2026

The 10-Q contains Dyne Therapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Dyne Therapeutics SEC Filing History

Browse Dyne Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
09/29/2026 3:10 PM
Dyne Therapeutics (1818794) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/08/2026 3:38 PM
Dyne Therapeutics (1818794) Subject
Kerr Douglas (1814189) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/08/2026 3:39 PM
Cox John (1498428) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/08/2026 3:13 PM
Cox John (1498428) Reporting
Dyne Therapeutics (1818794) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/08/2026 3:14 PM
Dyne Therapeutics (1818794) Issuer
Kerr Douglas (1814189) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/08/2026 3:15 PM
Dyne Therapeutics (1818794) Issuer
Friedl-Naderer Johanna (1915598) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/17/2026 4:30 PM
Dyne Therapeutics (1818794) Issuer
Rhodes Jason P (1577014) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/17/2026 3:06 PM
Dyne Therapeutics (1818794) Issuer
Lucera Erick (1697616) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/17/2026 3:07 PM
Cox John (1498428) Reporting
Dyne Therapeutics (1818794) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/14/2026 4:46 PM
Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/14/2026 4:47 PM
Atlas Venture Fund XI, L.P. (1708269) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/14/2026 4:47 PM
Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2026 4:36 PM
Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2026 4:36 PM
Atlas Venture Fund XI, L.P. (1708269) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2026 4:36 PM
Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2026 4:03 PM
Dyne Therapeutics (1818794) Subject
Kerr Douglas (1814189) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2026 4:03 PM
Dyne Therapeutics (1818794) Subject
Lucera Erick (1697616) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2026 4:04 PM
Cox John (1498428) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2026 3:51 PM
Atlas Venture Fund XI, L.P. (1708269) Filed by
Dyne Therapeutics (1818794) Subject
Form SCHEDULE 13G/A
08/13/2026 11:47 AM
Dyne Therapeutics (1818794) Subject
Janus Henderson Group Ltd. (1274173) Filed by
Form SCHEDULE 13G/A
08/06/2026 9:20 AM
Dyne Therapeutics (1818794) Subject
FMR LLC (315066) Filed by
Form SCHEDULE 13G/A
07/22/2026 4:19 PM
Dyne Therapeutics (1818794) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/22/2026 4:21 PM
Dyne Therapeutics (1818794) Filer
Form 424B5
07/21/2026 4:22 PM
Dyne Therapeutics (1818794) Filer
Form 424B5
07/20/2026 6:35 AM
Dyne Therapeutics (1818794) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/08/2026 4:35 PM
Dyne Therapeutics (1818794) Issuer
Rhodes Jason P (1577014) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/07/2026 4:05 PM
Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/07/2026 4:05 PM
Atlas Venture Fund XI, L.P. (1708269) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/07/2026 4:06 PM
Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/07/2026 4:06 PM
Atlas Venture Associates XI, L.P. (1780068) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/06/2026 4:17 PM
Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/06/2026 4:17 PM
Atlas Venture Fund XI, L.P. (1708269) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/06/2026 4:17 PM
Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/30/2026 6:05 PM
Dyne Therapeutics (1818794) Issuer
Rhodes Jason P (1577014) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/29/2026 4:49 PM
Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2026 4:50 PM
Atlas Venture Fund XI, L.P. (1708269) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2026 4:50 PM
Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/26/2026 4:04 PM
Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/26/2026 4:04 PM
Atlas Venture Fund XI, L.P. (1708269) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/26/2026 4:04 PM
Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/26/2026 7:40 AM
Dyne Therapeutics (1818794) Issuer
Rhodes Jason P (1577014) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
How Elon’s Empire Ends (and how to profit) (Ad)

Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days.tc pixel

See Chaikin's full research and the company name here
06/25/2026 4:28 PM
Atlas Venture Fund XI, L.P. (1708269) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/25/2026 4:29 PM
Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/25/2026 4:29 PM
Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/25/2026 4:11 PM
Dyne Therapeutics (1818794) Subject
Lucera Erick (1697616) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/24/2026 4:32 PM
Atlas Venture Fund XI, L.P. (1708269) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/24/2026 4:33 PM
Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/24/2026 4:36 PM
Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/24/2026 3:27 PM
Dyne Therapeutics (1818794) Issuer
Kersten Dirk (1823682) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2026 5:25 PM
Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/23/2026 5:26 PM
Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/23/2026 5:19 PM
Atlas Venture Fund XI, L.P. (1708269) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/23/2026 3:05 PM
Dyne Therapeutics (1818794) Issuer
Greene Barry E (1291963) Reporting
Form 3
Initial statement of beneficial ownership of securities  
06/23/2026 3:07 PM
Dyne Therapeutics (1818794) Issuer
Greene Barry E (1291963) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/22/2026 3:15 PM
Dyne Therapeutics (1818794) Issuer
Kersten Dirk (1823682) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/22/2026 3:15 PM
Dyne Therapeutics (1818794) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2026 3:03 PM
Dyne Therapeutics (1818794) Subject
ForDyne B.V. (2019392) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/17/2026 3:07 PM
Cox John (1498428) Reporting
Dyne Therapeutics (1818794) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2026 6:35 AM
Dyne Therapeutics (1818794) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/09/2026 4:09 PM
Dyne Therapeutics (1818794) Issuer
Stehman-Breen Catherine (1702233) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2026 4:12 PM
Dyne Therapeutics (1818794) Issuer
Incerti Carlo (1915358) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2026 4:12 PM
Dyne Therapeutics (1818794) Issuer
Kersten Dirk (1823682) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2026 4:13 PM
Dyne Therapeutics (1818794) Issuer
Rhodes Jason P (1577014) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2026 4:13 PM
Dyne Therapeutics (1818794) Issuer
Lubner David Charles (1572000) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2026 4:15 PM
Dyne Therapeutics (1818794) Issuer
HURWITZ EDWARD (1211840) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2026 4:06 PM
Dyne Therapeutics (1818794) Issuer
Posner Brian S (1372455) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/08/2026 3:05 PM
Dyne Therapeutics (1818794) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/03/2026 6:35 AM
Dyne Therapeutics (1818794) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/15/2026 11:36 AM
Dyne Therapeutics (1818794) Subject
JANUS HENDERSON GROUP PLC (1274173) Filed by
Form SCHEDULE 13G/A
05/14/2026 3:04 PM
Dyne Therapeutics (1818794) Issuer
Kerr Douglas (1814189) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2026 3:05 PM
Dyne Therapeutics (1818794) Issuer
Friedl-Naderer Johanna (1915598) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2026 3:55 PM
Dyne Therapeutics (1818794) Subject
Lucera Erick (1697616) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/13/2026 3:57 PM
Cox John (1498428) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/11/2026 6:25 AM
Dyne Therapeutics (1818794) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/11/2026 6:35 AM
Dyne Therapeutics (1818794) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/06/2026 4:09 PM
Dyne Therapeutics (1818794) Issuer
Rhodes Jason P (1577014) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/06/2026 3:42 PM
Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/06/2026 3:42 PM
Atlas Venture Associates XI, L.P. (1780068) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/06/2026 3:43 PM
Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/06/2026 10:13 AM
Dyne Therapeutics (1818794) Subject
FMR LLC (315066) Filed by
Form SCHEDULE 13G
05/05/2026 3:36 PM
Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/05/2026 3:36 PM
Atlas Venture Associates XI, L.P. (1780068) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/05/2026 3:37 PM
Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/04/2026 3:59 PM
Atlas Venture Associates XI, L.P. (1780068) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/04/2026 3:59 PM
Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/04/2026 3:59 PM
Atlas Venture Fund XI, L.P. (1708269) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/04/2026 4:00 PM
Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/30/2026 4:22 PM
Dyne Therapeutics (1818794) Issuer
Rhodes Jason P (1577014) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 3:56 PM
Dyne Therapeutics (1818794) Issuer
Lubner David Charles (1572000) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 3:42 PM
Atlas Venture Associates XI, L.P. (1780068) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/28/2026 3:43 PM
Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Trump's New Dollar (Ad)

Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel

Watch the free briefing and see the three steps to prepare today
04/28/2026 3:43 PM
Atlas Venture Fund XI, L.P. (1708269) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/28/2026 3:44 PM
Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 5:15 PM
Dyne Therapeutics (1818794) Issuer
Rhodes Jason P (1577014) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/27/2026 3:48 PM
Atlas Venture Associates XI, L.P. (1780068) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 3:48 PM
Atlas Venture Fund XI, L.P. (1708269) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 3:48 PM
Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 3:49 PM
Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/24/2026 3:45 PM
Atlas Venture Associates XI, L.P. (1780068) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/24/2026 3:46 PM
Atlas Venture Fund XI, L.P. (1708269) Reporting
Dyne Therapeutics (1818794) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)

Dyne Therapeutics SEC Filings - Frequently Asked Questions

Dyne Therapeutics (DYN) has submitted 592+ filings to the SEC since 2020. You can browse the complete history or filter by form type using the tools above.

Dyne Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Dyne Therapeutics's financial statements page.

The most recent filing was a Form 8-K submitted on September 29, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:DYN are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 9/29/2026. New filings are added as they're published.
From Our Partners